je.st
news
Rexahn Awarded Patent In Europe For Cancer Drug Archexin
2013-10-02 07:43:36| drugdiscoveryonline News Articles
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, recently announced that the European Patent Office has granted the Company a patent, EP 1546180, for its clinical development candidate Archexin and its use for inhibiting the activated form of Akt-1 (phospho-Akt1)for the treatment of cancer
Tags: europe
drug
cancer
patent
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||